Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods

Cancer Chemotherapy and Pharmacology

Volumn 40, Issue 4, 1997, Pages 293-308

  Stewart, David J ^a,b   Dulberg, Corinne S ^b   Mikhael, Nadia Z ^b   Redmond, M Deidre ^a   Montpetit, Vital A J ^b   Goel, Rakesh ^a,b  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Administration; Cisplatin; Nephrotoxicity

Indexed keywords

BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLEOMYCIN; CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; DIGOXIN; DOXORUBICIN; FOLIC ACID; GLYCERYL TRINITRATE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LORAZEPAM; MANNITOL; METHYLXANTHINE DERIVATIVE; METOCLOPRAMIDE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYTOIN; PLATINUM; POTASSIUM; PROCHLORPERAZINE; SERUM ALBUMIN; UNINDEXED DRUG; URIC ACID; VINCA ALKALOID;

ARTICLE; AUTOPSY; BODY SURFACE; CANCER CHEMOTHERAPY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HYDRATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CORTEX; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RETROSPECTIVE STUDY;

ANTINEOPLASTIC AGENTS; CISPLATIN; CREATININE; FEMALE; HUMANS; KIDNEY; KIDNEY DISEASES; LOGISTIC MODELS; MALE; NEOPLASMS; PLATINUM; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0030997613     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050661     Document Type: Article

References (63)

1. Hayes DM, Cvitkovic E, Golbey RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cisplatinum diammine dichloride. Cancer 39: 1372-1381
2. Osman NM, Copley MP, Litterst CL (1984) Effects of the diuretics mannitol or acetazolamide on nephrotoxicity and physiological disposition of cisplatin in rats. Cancer Chemother Pharmacol 13: 58-62
3. Pera MF Jr, Zook BC, Harder HC (1979) Effects of mannitol or furosemide diuresis on the nephrotoxicity and physiological disposition of cis-dichlorodiammineplatinum-(II) in rats. Cancer Res 39: 1269-1278
4. Osman NM, Copley MP, Litterst CL (1984) Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats. Cancer Treat Rep 68: 999-1004
5. Al-Sarraf M, Fletcher W, Oishi N, Pugh R, Hewelett JS, Balducci L, McCracken J, Padilla F (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma. Cancer Treat Rep 66: 31-35
6. Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pretreatment on clinical, morphological and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5: 1393-1399
7. 195mplatinum cis-dichlorodiammineplatinum(II). Cancer Treat Rep 63: 951-960
8. Ward JM, Grabin ME, LeRoy AF, Young DM (1977) Modification of the renal toxicity of cis-dichlorodiammineplatinum(II) with furosemide in male F344 rats. Cancer Treat Rep 61: 375-379
9. Jones MM, Basinger MA (1989) Thiol and thioether suppression of cis-platinum-induced nephrotoxicity in rats bearing the Walker 256 carcinosarcoma. Anticancer Res 9: 1937-1942
10. Nechay BR, Neldon SL (1984) Characteristics of inhibition of human renal adenosine triphosphatases by cisplatin and chloroplatinic acid. Cancer Treat Rep 68: 1135-1141
11. Wagner T, Kreft B, Bohlmann G, Schwieder G (1988) Effects of fosfomycin, mesna, and sodium thiosulfate on the toxicity and antitumor activity of cisplatin. J Cancer Res Clin Oncol 114: 497-501
12. Jones MM, Basinger MA, Mitchell WM, Bradley CA (1986) Inhibition of cis-diamminedichloroplatinum(II) -induced renal toxicity in the rat. Cancer Chemother Pharmacol 17: 38-42
13. Kempf SR, Ivankovic S, Wiessler M, Schmahl D (1985) Effective prevention of the nephrotoxicity of cis-platin (CDDP) by administration of sodium 2-mercaptoethane-sulfonate (MESNA) in rats. Br J Cancer 52: 937-939
14. Naganuma A, Satoh M, Imura N (1984) Effect of copper pretreatment on toxicity and antitumor activity of cis-diamminedichloroplatinum in mice. Res Commun Chem Pathol Pharmacol 46: 265-274
15. Ohkawa K, Tsukada Y, Dohzono H, Koike K, Terashima Y (1988) The effects of co-administration of selenium and cis-platin (CDDP) on CDDP-induced toxicity and antitumour activity. Br J Cancer 58: 38-41
16. Baldew GS, van den Hamer CJA, Los G, Vermeulen NPE, de Goeij JJM, McVie JG (1989) Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats. Cancer Res 49: 3020-3023
17. Berry JP, Lespinats G (1988) Cis DDP in combination with selenium and sulfur. Subcellular effect in kidney cells. Electron microprobe study. J Submicrosc Cytol Pathol 20: 59-65
18. Naganuma A, Satoh M, Imura N (1987) Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Research 47: 983-987
19. Dardas G, Fadool J, Aggarwal SK (1987) Calcium as an effective antagonist to cisplatin toxicities. Fed Proc 46: 1395
20. Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54: 19-23
21. Kramer RA (1989) Protection against cisplatin nephrotoxicity by prochlorperazine. Cancer Chemother Pharmacol 25: 156-160
22. Esposito M, Fulco RA, Collecchi P, Zicca A, Cadoni A, Merlo F, Rosso R, Sobrero A (1990) Improved therapeutic index of cisplatin by procaine hydrochloride. J Natl Cancer Inst 82: 677-684
23. Offerman JJG, Sleijfer DT, Mulder NH, Meijer S, Koops HS, Donker AJM (1985) The effect of captopril on renal function in patients during the first cis-diamminedichloroplatinum II infusion. Cancer Chemother Pharmacol 14: 262-264
24. Sleijfer DT, Offerman JJG, Mulder NH, Verweij M, Van Der Hem GK, Koops HS, Meijer S (1987) The protective potential of the combination of verapamil and cimetidine on cisplatin-induced nephrotoxicity in man. Cancer 60: 2823-2828
25. Mayer RD, Lee K, Cockett ATK (1987) Inhibition of cisplatin-induced nephrotoxicity in rats by buthionine sulfoximine, a glutathione synthesis inhibitor. Cancer Chemother Pharmacol 20: 207-210
26. Mayer RD, Lee K, Cockett ATK (1989) Improved use of buthionine sulfoximine to prevent cisplatin nephrotoxicity in rats. J Cancer Res Clin Oncol 115: 418-422
27. Jacobs C, Kaubisch S, Halsey J, Lum BL, Gosland M, Coleman CN, Sikic BI (1991) The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer 67: 1518-1524
28. Hayashi T, Watanabe Y, Kumano K, Kitayama R, Muratani T, Yasuda T, Saikawa I, Katahira J, Kumada T, Shimizu K (1989) Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats. Antimicrob Agents Chemother 33: 513-518
29. Jones R, Fant W, Cacini W (1987) Protective effect of organic cations on cisplatin-induced toxicity to renal cortex. Fed Proc 46: 1294
30. Earhart RH, Martin PA, Tutsch KD, Erturk E, Wheeler RH, Bull FE (1983) Improvement in the therapeutic index of cis-platin (NSC 119875) by pharmacologically induced chloruresis in the rat. Cancer Res 43: 1187-1194
31. Holleran WM, DeGregorio MW (1988) Evolution of high-dose cisplatin. Invest New Drugs 6: 135-142
32. Salem PA, Jabboury KW, Khalil MF (1982) Severe nephrotoxicity: a probable complication of cis-dichlorodiammineplatinum(II) and cephalothin-gentamicin therapy. Oncology 39: 31-32
33. Jongejan HTM, Provoost AP. Molenaar JC (1988) Potentiation of cis-diamminedichloroplatinum nephrotoxicity by amikacin in rats. Cancer Chemother Pharmacol 22: 178-180
34. Daley-Yates PT, McBrien DCH (1984) Enhancement of cis-platin nephrotoxicity by probenecid. Cancer Treat Rep 68: 445-446
35. Appenroth D, Winnefeld K (1993) Role of glutathione for cisplatin nephrotoxicity in young and adult rats. Renal Failure 15: 135-139
36. Campbell AB, Kalman SM, Jacobs C (1983) Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treat Rep 67: 169-172
37. Kelsen DP, Alcock N, Young CW (1985) Cisplatin nephrotoxicity: correlation with plasma platinum concentrations. Am J Clin Oncol 8: 77-80
38. Reece PA, Stafford I, Russell IJ, Khan M, Grantley Gill P (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5: 304-309
39. Jacobs C, Bertino JR, Goffinet DR, Fee WE, Goode RL (1978) 24-hour infusion of cisplatin in head and neck cancers. Cancer 42: 2135-2140
40. Salem P, Khalyl M, Jabboury K, Hashimi L (1984) Cis-diammine-dichloroplatinum (II) by 5-day continuous infusion. Cancer 53: 837-840
41. Izumi T (1988) Experimental studies on the nephrotoxicity of cisplatin amelioration of nephrotoxicity by continuous infusion. Hinyokika Kiyo 34: 37-45
42. Cavaletti G, Tredici G, Pizzini G, Minoia A (1990) Tissue platinum concentrations and cisplatin schedules. Lancet 336: 1003
43. Levi F, Benavides M, Chevelle C, Le Saunier F, Bailleul F, Misset J-L, Regensberg C, Vannetzel J-M, Reinberg A, Mathe G (1990) Chemotherapy of advanced ovarian cancer with 4′-O-tetrahydropyranyl doxorubicin and cisplatin: a randomized phase II trial with an evaluation of circadian timing and dose-intensity. J Clin Oncol 8:705-714
44. Hrushcsky WJM (1984) Selected aspects of cisplatin nephrotoxicity in the rat and man. Dev Oncol 17:165-186
45. Stewart DJ, Mikhael NZ, Nanji AA, Nair RC, Kacew S, Howard K, Hirte W, Maroun JA (1985) Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose and nephrotoxicity. J Clin Oncol 3: 1251-1256
46. Stewart DJ, Dulherg C, Molepo JM, Mikhael NZ, Montpetit VAJ, Redmond MD, Goel R (1994) Factors affecting human autopsy kidney cortex and kidney medulla platinum concentrations after cisplatin. Cancer Chemother Pharmacol: 34: 14-22
47. Terheggen PMAB, Floot BGJ, Scherer E, Begg AC, Fichtinger-Schepman AMJ, Engelse LD (1987) Immunocytochemical detection of interaction products of cis-diamminedichloroplutinum(II) and cis-diammine (1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections. Cancer Res 47: 6719-6725
48. Nanji AA, Stewart DJ, Mikhael NZ (1986) Hyperuricemia and hypoalbuminemia predispose to cisplatin-induced nephrotoxicity. Cancer Chemother and Pharmacol 17: 274-276
49. Repta AJ, Long DF (1980) Reactions of cisplatin with human plasma and plasma fractions. In: Prestayko AW, Crooke ST, Carter SK (eds) Cisplatin: current status and new developments. Academic Press, New York, pp 285-304
50. Brenner BM, Troy JL (1971) Postglomerular vascular protein concentration. Evidence for a causal role in governing fluid reabsorption and glomerular balance by the proximal tubule. J Clin Invest 50: 336-341
51. Lee YK, Shin DM (1992) Renal salt wasting in patients treated with high-dose cisplatin, etoposide, and mitomycin in patients with advanced non-small cell lung cancer. Korean J Int Med 7: 118-121
52. Hostetter TH, Brenner BM (1994) Tubulointerstitial diseases of the kidney. In: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds) Harrison's principles of internal medicine, 13th edn. McGraw-Hill, New York, p 1317
53. Stewart DJ, Grewaal D, Popovic P, Molepo JM, Mikhael NZ, MacDonald H, Goel R (1995) Effect of cations on cisplatin uptake and efficacy in lung cancer cell lines. Proc Am Assoc Cancer Res 36: 399
54. Stewart DJ, Molepo M, Green RM, Montpetit VAJ, Hugenholtz H, Lamothe A, Mikhael NZ, Redmond MD, Goel R (1995) Factors affecting platinum concentrations in human surgical tumour specimens after cisplatin. Br J Cancer 71: 598-604
55. Rail TW, Schleifer LS (1990) Drugs effective in the therapy of the epilepsies. In: Gilman AG, Rall TW, Nies AS, Taylor P (eds) Goodman and Gilman's the pharmacological basis of therapeutics, 8th edn., Pergamon Press, New York, pp 436-462
56. Buyan RD, Schroeder RL, Perkins WE (1985) Lack of effect of metoclopramide on cisplatin-induced nephrotoxicity in rats. Res Commun Chem Pathol Pharmacol 50: 135-138
57. Israel R, O'Mara V, Austin B, Bellucci A, Meyer BR (1986) Metoclopramide decreases renal plasma flow. Clin Pharm Ther 39: 261-264
58. Lybak S, Wennerberg J, Kjellen E, Pero RW (1991) Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck. Anticancer Drugs 2: 375-382
59. Johnsson A, Kjellen E, Wennerberg J, Pero R (1996) Metoclopramide as a modulator of cisplatin: effects on pharmacokinetics and cisplatin-DNA adducts in tumor and normal tissue. Anticancer Drugs 7: 483-488
60. Smith JH, Smith MA, Litterst CL, Copley MP, Uozumi J, Boyd MR (1988) Comparative toxicity and renal distribution of the platinum analogs tetraplatin. CHIP, and cisplatin at equimolar doses in the Fischer 344 rat. Fundam Appl Toxicol 10: 45-61
61. Gonzalez-Vitale JC, Hayes DM, Cvhkovic E, Sternberg S (1977) The renal pathology in clinical trials of cis-platinum(II) diamminedichloride. Cancer 39: 1362-1371
62. Gregg RW, Stewart DJ, Molepo JM, Montpetit, VJA, Mikhael NZ, Redmond D, Gadia M (1992) Cisplatin neurotoxicity the relationship between dosage, time, platinum concentration in neurological tissues and morphological evidence of toxicity. J Clin Oncol 10: 795-803
63. Stewart DJ, Grewaal D, Redmond D, Mikhael N, Montpetit V, Goel R, Green R (1993) Human autopsy tissue distribution of the epipodophyllotoxins etoposide and teniposide. Cancer Chemother Pharmacol 32: 368-372